




DESORDEN BIPOLARIDAD

Jean Louis Lozada Dominguez

¿Qué es el desorden de Bipolaridad?

- Es una enfermedad mental que se caracteriza por periodos de depresión y animo elevado inusual, conocido como Manía. Según Tobias A. Rowland, es una enfermedad multidimensional que involucra el ánimo, déficits neuro físicos, inmunológicos y cambios físicos en los individuos que se ven afectados.




Tipos de Bipolaridad

- Desorden Bipolar tipo I
- Desorden Bipolar tipo 2
- Desorden Bipolaridad Ciclotímico
- Desorden de Bipolaridad por abuso de sustancia o medicina

https://images.search.yahoo.com/search/images?p=hypomania&fr=mcafee&type=E211US105G91508&imgurl=http%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSpecial%3AFilePath%2FBipolar_mood_shifts.png&id=-1&iurl=http%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSpecial%3AFilePath%2FBipolar_mood_shifts.png&action=click

Bipolaridad a nivel Neurobiológico

- Cambios en el cerebro como:
 - Disminución en volumen bilateral del hipocampo, amígdala y tálamo
 - Aumento en volumen de ventrículos laterales
 - Cambios en niveles de Calcio intracelulares



<https://finalpsychologyproject10.weebly.com/bipolar-disorder.html>

Medicamentos para Bipolaridad

- Comenzó con varios, pero resaltaron los barbitúricos
- Sales de litio
- Litio
- Acido valproico, anticonvulsivante
- Carbamazepina, antiepiléptico
- Antipsicóticos y anti depresivos
- Anti inflamatorios

COMMON BIPOLAR TREATMENTS

MOOD STABILIZERS

These aptly named meds help even out the swings, lessening the chance of high highs and low lows. Give 'em time to work: They take few weeks to kick in.



ANTIPSYCHOTICS

These faster acting drugs begin easing symptoms within a few hours, so they can have your back while mood stabilizers are doing their slow-and-steady thing.



ECT

When medication just isn't working well, electroconvulsive therapy can be a good option for people with bipolar. It's even safe to do during pregnancy.




TALK THERAPY

Working with a therapist helps you better understand your emotions while learning important strategies to help you cope with your condition.



Mejora en
calidad de
vida



<https://www.verywellmind.com/treating-bipolar-disorder-3576129>



Tratamientos inovadores

- Medicina genética
- Combinación de medicamentos
- Medicamentos dirigidos a control de Calcio
- Mejora en modelos celulares y animales
- Caracterización del genotipo de la enfermedad

Referencias:

- Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. *Molecular Psychiatry*, 24(2), 198–217. <https://doi.org/10.1038/s41380-018-0044-2>
- Bonnín, C. D. M., Reinares, M., Martínez-Arán, A., Jiménez, E., Sánchez-Moreno, J., Solé, B., Montejo, L., & Vieta, E. (2019). Improving Functioning, Quality of Life, and Well-being in Patients With Bipolar Disorder. *The International Journal of Neuropsychopharmacology*, 22(8), 467–477. <https://doi.org/10.1093/ijnp/pyz018>
- Fries, G. R., Walsb-Bass, C., Bauer, M. E., & Teixeira, A. L. (2019). Revisiting inflammation in bipolar disorder. *Pharmacology Biochemistry and Behavior*, 177, 12–19. <https://doi.org/10.1016/j.pbb.2018.12.006>
- Gordovez, F. J. A., & McMahon, F. J. (2020). The genetics of bipolar disorder. *Molecular Psychiatry*, 25(3), 544–559. <https://doi.org/10.1038/s41380-019-0634-7>
- Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. *The Lancet*, 387(10027), 1561–1572. [https://doi.org/10.1016/S0140-6736\(15\)00241-X](https://doi.org/10.1016/S0140-6736(15)00241-X)
- Harrison, P. J., Cipriani, A., Harmer, C. J., Nobre, A. C., Saunders, K., Goodwin, G. M., & Geddes, J. R. (2016). Innovative approaches to bipolar disorder and its treatment. *Annals of the New York Academy of Sciences*, 1366(1), 76–89. <https://doi.org/10.1111/nyas.13048>
- Harrison, P. J., Geddes, J. R., & Tunbridge, E. M. (2018). The Emerging Neurobiology of Bipolar Disorder. *Trends in Neurosciences*, 41(1), 18–30. <https://doi.org/10.1016/j.tins.2017.10.006>
- Hibar, D. P., Westlye, L. T., Van Erp, T. G. M., Rasmussen, J., Leonardo, C. D., Faskowitz, J., Haukvik, U. K., Hartberg, C. B., Doan, N. T., Agartz, I., Dale, A. M., Gruber, O., Krämer, B., Trost, S., Liberg, B., Abé, C., Ekman, C. J., Ingvar, M., Landén, M., ... Andreassen, O. A. (2016). Subcortical volumetric abnormalities in bipolar disorder. *Molecular Psychiatry*, 21(12), 1710–1716. <https://doi.org/10.1038/mp.2015.227>
-
- Hibar, D. P., Westlye, L. T., Doan, N. T., Jahanshad, N., Cheung, J. W., Ching, C. R. K., Versace, A., Bilderbeck, A. C., Uhlmann, A., Mwangi, B., Krämer, B., Overs, B., Hartberg, C. B., Abe, C., Dima, D., Grotegerd, D., Sprooten, E., Ben, E., Jimenez, E., ... Andreassen, O. A. (2018). Cortical abnormalities in bipolar disorder: An MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. *Molecular Psychiatry*, 23(4), 932–942. <https://doi.org/10.1038/mp.2017.73>
- López-Muñoz, F., Shen, W. W., D'oon, P., Romero, A., & Álamo, C. (2018). A history of the pharmacological treatment of bipolar disorder. *International Journal of Molecular Sciences*, 19(7), 1–38. <https://doi.org/10.3390/ijms19072143>
- Rosenblat, J. D. (2019). Targeting the immune system in the treatment of bipolar disorder. *Psychopharmacology*, 236(10), 2909–2921. <https://doi.org/10.1007/s00213-019-5175-x>
- Rowland, T. A., & Marwaha, S. (2018). Epidemiology and risk factors for bipolar disorder. *Therapeutic Advances in Psychopharmacology*, 8(9), 251–269. <https://doi.org/10.1177/2045125318769235>